@misc{indiciaeaddb1be4e574,
  title = {Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial.},
  author = {Rafal Dziadziuszko and Jin Seok Ahn and Fabrice Barlesi and Benjamin J Solomon and Yi-Long Wu and Igor Bondarenko and Maximilian Hochmair and Hidehito Horinouchi and Dae Ho Lee and Jong-Seok Lee and David Planchard and Achim Rittmeyer and Wenzhao Zhong and Leah Adler and Venice Archer and Andres Cardona and Patricia Petric and Astrid Scalori and Beiying Ding and Carla Mamolo and Vlatka Smoljanovic and Makoto Nishio},
  year = {2026},
  doi = {10.1016/s1470-2045(26)00283-4},
  url = {https://pubmed.ncbi.nlm.nih.gov/42636834/},
  note = {Source identifier: 42636834}
}